US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Drug Discovery: market research reports

RSS Feeds

Drug Discovery market research reports and industry analysis

1    3    5  6  7  8  9  10  
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... 366 Alpha6Beta4 integrin pathway targeting drugs in 1258 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 164 drugs. ...  |  read more...
$5,622.50
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... leads to activation of several non-receptor tyrosine kinases including those of the Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules. There are today 214 companies plus ...  |  read more...
$5,622.50
Brain Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are ...  |  read more...
$5,622.50
Calcium Signaling Pathway in Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... suspended drug and the accumulated number of ceased drugs over the last years amount to another 101 drugs. Calcium Signaling Pathway In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis ...  |  read more...
$5,622.50
Cell Cycle Targeting in Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... suspended drugs and the accumulated number of ceased drugs over the last years amount to another 108 drugs. Cell Cycle Targeting In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis ...  |  read more...
$5,622.50
Conjugated Drugs in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... targeting, the clinical application of ADCs is accelerating rapidly. But antibodies are not the only kind of compound one could conjugate small molecules to, nor the only class of compounds which one can yield targeted ...  |  read more...
$5,622.50
Cytokine Therapy in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... accumulated number of ceased drugs over the last years amount to another 7 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ...  |  read more...
$3,747.50
EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 304 drugs. Egfr1 Signaling Pathway In Oncology Drug Pipeline Update lists ...  |  read more...
$5,622.50
Epigenetic Therapy in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... autoimmunity, diabetes, or neurological disorders. Recent research has identified the set of enzymes and chromatin-binding proteins responsible for regulating chromatin structure. These enzymes and binding proteins form the cell’s toolkit for epigenetic regulation by opening ...  |  read more...
$3,747.50
ErbB Signaling Pathway in Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces ...  |  read more...
$5,622.50
FSH Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... FSH signaling which continues further downstream. Activation of PKA leads to phosphorylation of transcription factors like cAMP response element binding protein(CREB) and brings about chromatin remodeling by phosphorylating histone H3. It also enhances the activity ...  |  read more...
$5,622.50
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... drugs in 1260 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 146 drugs. Il-2 Signaling Pathway In Oncology ...  |  read more...
$5,622.50
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... 642 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 64 drugs. Il-5 Signaling Pathway In Oncology Drug Pipeline ...  |  read more...
$5,622.50
Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. There are today 366 companies plus partners developing 566 cytokine-cytokine receptor interaction ...  |  read more...
$5,622.50
Jak-STAT Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. There are today 247 companies plus ...  |  read more...
$5,622.50
Leukemia Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 126 drugs. Leukemia Drug Pipeline Update lists all drugs and gives ...  |  read more...
$5,622.50
Lung Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe ...  |  read more...
$5,622.50
Lymphoma Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 107 drugs. Lymphoma Drug Pipeline Update lists all drugs and gives you ...  |  read more...
$5,622.50
Melanoma Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... R&D, five-year survival of advanced patients remains below 20%. There are today 266 companies plus partners developing 311 drugs targeting melanoma in development. In addition, there are 3 suspended drugs and the accumulated number of ...  |  read more...
$5,622.50
mTOR Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... several hallmarks of cancer such as cell growth and proliferation, angiogenesis, and bioenergetics. Since mTOR acts as a neoplastic switch that is frequently turned on by many mutations found in cancer, inhibition of mTOR may ...  |  read more...
$5,622.50
NOD-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... more than 20 members in mammals and plays a pivotal role in the recognition of intracellular ligands. There are today 86 companies plus partners developing 75 NOD-like receptor signaling pathway targeting drugs in 227 developmental ...  |  read more...
$3,747.50
Notch Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... are today 249 companies plus partners developing 343 Notch pathway targeting drugs in 1214 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last ...  |  read more...
$5,622.50
Orphan Drugs in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... not only to those cancer indications in which drugs are being granted orphan drug status, but also detailed insights in to their mechanism of action and developmental strategy. The orphan drug designation is designed to ...  |  read more...
$5,622.50
Peptides in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... number of ceased drugs over the last years amount to another 127 drugs. Peptides In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs ...  |  read more...
$5,622.50
PI3K-Akt Signaling Pathway in Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... translation, proliferation, growth, and survival. There are today 462 companies plus partners developing 839 PI3K-Akt signaling pathway targeting drugs in 2654 developmental projects in cancer. In addition, there are 11 suspended drugs and the accumulated ...  |  read more...
$7,497.50
1    3    5  6  7  8  9  10  
 
Our Clients